Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 280 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Testosterone Therapy Clear all

Conditions: Hypoactive Sexual Desire Disorder
Interventions: testosterone gel, placebo gel; Drug
Lead sponsor: BioSante Pharmaceuticals; Industry
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 575 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 66
States / cities: Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 60 more

Conditions: Healthy, Men, Male Contraception
Interventions: Nestorone + Testosterone Combination Gel; Drug
Lead sponsor: Premier Research; Other
Eligibility: 18 Years to 50 Years
Enrollment: 420 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 9
States / cities: Sacramento, California • Torrance, California • Denver, Colorado + 6 more

Conditions: Hypoactive Sexual Desire Disorder (HSDD)
Interventions: Placebo Vaginal Insert, Prasterone 6.5 mg (0.50%) Vaginal Insert; Drug
Lead sponsor: EndoCeutics Inc.; Industry
Eligibility: 40 Years to 80 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 10
States / cities: Huntsville, Alabama • San Diego, California • New London, Connecticut + 7 more

Conditions: Pain, Gender Identity
Interventions: Quantative sensory testing, Blood Draw; Behavioral · Diagnostic Test
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hypogonadism, Hypogonadism, Male, Hypogonadotropic Hypogonadism
Interventions: Aveed Injectable Product, Fortesta, Testim; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 673 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 35
States / cities: Birmingham, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 27 more

Conditions: PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction, Brain Trauma, Brain Injuries
Interventions: Hormone Replacement Therapy (HRT), Magnetic Resonance Therapy (MeRT), ibogaine with magnesium treatment, 5-MeO-DMT; Other · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Burns
Interventions: Stable Isotope Infusion Study, Collection of blood and tissues, Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI, Humatrope, Ketoconazole, Oxandrolone, Propranolol, Oxandrolone and propranolol combined, Humatrope and propranolol combined, Placebo, Exercise--Hospital supervised intensive exercise program, Home exercise program; Procedure · Drug · Behavioral
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: Up to 80 Years
Enrollment: 1,126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2019
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Transgender, Transgenderism
Interventions: Not listed
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 12 Years to 30 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Breast Cancer, Gynecologic Cancer
Interventions: prasterone, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 280
States / cities: Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 185 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Placebo Oral Tablet, Fluoxetine, DHEA, Fluoxetine and DHEA; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 50 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypogonadism
Interventions: 10.0 mg of Testosterone, 4.0% TID, 13.5 mg of Testosterone, 4.5% B.I.D, 11.25 mg of Testosterone, 4.5% T.I.D; Drug
Lead sponsor: Acerus Pharmaceuticals Corporation; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 3
States / cities: Tucson, Arizona • Miami, Florida • Shreveport, Louisiana

Conditions: Cachexia, Squamous Cell Carcinoma
Interventions: Placebo Testosterone, Testosterone Enanthate 100 MG/ML; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Primary Ovarian Insufficiency, Unexplained Infertility
Interventions: Dehydroepiandrosterone, Placebo; Dietary Supplement · Other
Lead sponsor: Center for Human Reproduction; Other
Eligibility: 21 Years to 37 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Brain and Central Nervous System Tumors, Musculoskeletal Complications
Interventions: testosterone gel applied to skin, whey powder protein; Drug · Dietary Supplement
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Sleep Apnea, Obstructive, Sleep Apnea, Hypotestosteronism
Interventions: Not listed
Lead sponsor: Lahey Clinic; Other
Eligibility: 18 Years to 70 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 2
States / cities: Burlington, Massachusetts • Peabody, Massachusetts

Conditions: Menopause, Sexual Dysfunction, Libido Disorder, Testosterone Deficiency
Interventions: Transdermal testosterone gel, Transdermal placebo gel; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: Clomiphene Citrate 25mg; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older · Male only
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2037
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Alzheimer's Disease, Hypogonadism
Interventions: AndroGel (Solvay Pharmaceuticals); Drug
Lead sponsor: Michael E. DeBakey VA Medical Center; Federal
Eligibility: 55 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Anorexia Nervosa, Eating Disorder, Anxiety, Depression
Interventions: Testosterone, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Castration Resistant Metastatic Prostate Cancer
Interventions: Testosterone cypionate, Enzalutamide, Testosterone enanthate; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 6
States / cities: San Diego, California • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: Low Bone Mass, Osteoporosis, Postmenopausal
Interventions: DHEA, Placebo, Exercise; Other · Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 55 Years to 85 Years · Female only
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hypogonadism
Interventions: Oral testosterone undecanoate (TU) (300 mg T equivalents/dose), Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose), Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food), Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (300 mg T equivalents/dose); Drug
Lead sponsor: Clarus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 68 Years · Male only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 4
States / cities: Birmingham, Alabama • Los Angeles, California • San Antonio, Texas

Conditions: Contraception
Interventions: Nestorone gel, Testosterone Gel; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: Torrance, California • Seattle, Washington

Conditions: Primary Ovarian Insufficiency, Female Infertility Due to Diminished Ovarian Reserve
Interventions: Testosterone cream (0.5mg per gram), DHEA, Placebo; Drug · Dietary Supplement
Lead sponsor: Center for Human Reproduction; Other
Eligibility: 38 Years to 44 Years · Female only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 2
States / cities: New York, New York • Rochester, New York

Search by objective public record fields.

Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

Study of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study

State of Hormones Impact Nociceptive Expression

A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism

Trifecta Research Study

Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation

Cardiometabolic Health in Transgender Males

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

The Effects of Fluoxetine and/or DHEA

Efficacy of an Intranasal Testosterone Product

Testosterone for Treating Cachexia in Patients With Squamous Cell Carcinoma

Study of Oral Dehydroepiandrosterone(DHEA) to Treat Previously Unexplained Infertility

Testosterone Gel in Preventing Weakness Caused by Steroid Therapy in Men With Glioma

Sexual Dysfunction And Hypotestosteronemia In Patients With Obstructive Sleep Apnea Syndrome

Transdermal Testosterone Gel for Female Sexual Interest and Arousal Disorder in Peri- and Post Menopause

HRT-PC Trial: Hormone Recovery After Treatment for Prostate Cancer Trial. An Open-label Phase II Study of Clomiphene Citrate in Patients With Persistent Hypogonadism After ADT for Treatment of Localized Prostate Cancer

Effect of Testosterone Therapy in Men With Alzheimer's Disease and Low Testosterone

Hormonal Factors in the Treatment of Anorexia Nervosa

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

DHEA Augmentation of Musculoskeletal Adaptations to Exercise in Older Women

Pharmacokinetic Study of Oral Testosterone (T) Ester Formulations in Hypogonadal Men

NES Gel-1, To Evaluate Nestorone Gel in Combination With Testosterone Gel

Effect of Testosterone Treatment on Embryo Quality